Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Colchicine added to standard therapy for chronic urticaria
IRCT20200406046967N1Phase 3Completed
- Sponsor
- Shiraz University of Medical Sciences
- Start
- May 2020
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of colchicine in chronic urticaria (CU) (2 arms), sponsored by Shiraz University of Medical Sciences. Primary endpoints: Reduction in autoantibody levels and urticaria symptoms after colchicine treatment, UAS7 score change and 3 more. Started May 2020; status: completed.
02
Drugs
colchicine
03
Conditions
chronic urticaria (CU)
Beyond the preview
Go deeper on IRCT20200406046967N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200406046967N1.